If approved, CUTX-101 will be the first and only FDA-approved treatment available for Menkes disease, a rare X-linked ...

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a ...

The drug, CUTX-101, is intended for the treatment of Menkes disease, a rare X-linked recessive genetic disorder affecting ...

On market launch of the product, Formycon will receive a mid–double-digit-share of gross profits in the region.

Sentynl Therapeutics, a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, have announced that the U.S. Food and Drug Administration (FDA) has accepted ...

Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the ...

Track 11 major stocks including SBI, HDFC Bank, MTNL, and Zydus Lifesciences for key deals, orders, and updates—read more now ...

Ahmedabad: Zydus has announced that the company has received the Establishment Inspection Report (EIR) from the U.S. Food and ...

Zydus will commercialise FYB206 in North America, while Formycon will lead development, regulatory filings and supply, with a ...

Formycon AG will be responsible for the development, registration, manufacture and supply of the product. Zydus Lifesciences ...

India’s Zydus Lifesciences is in the FDA’s crosshairs once again, this time for a trio of unnamed violations at an injectables facility. Following an FDA inspection that wrapped up this week, Zydus, ...

Zydus Lifesciences' UAE-based unit has partnered with Formycon AG for a biosimilar supply deal in the US and Canada. This ...